TY - JOUR
T1 - Different transmission routes and the risk of advanced HIV disease
T2 - A systematic review and network meta-analysis of observational studies
AU - Chen, Qiaosen
AU - Zeng, Ding
AU - She, Yangyang
AU - Lyu, Yuhan
AU - Gong, Xiao
AU - Feinstein, Matthew J.
AU - Yang, Yi
AU - Jiang, Hongbo
N1 - Funding Information:
National Natural Science Foundation of China (81703282).
Funding Information:
This work was funded by National Natural Science Foundation of China (81703282). The funding source of the study had no role in the study design, data collection, data analysis, data interpretation, writing of the report, or in the decision to submit the paper for publication.
PY - 2019/11
Y1 - 2019/11
N2 - Background: A substantial proportion of people living with HIV (PLHIV) present for care with advanced HIV disease (AHD), which may result in difficulty reaching the “90–90–90” target to end AIDS in 2030. We assessed the risk of AHD for different transmission routes to summarize the evidence for priority prevention strategies for key populations. Methods: Observational studies published before September 10th, 2019 in the PubMed, EMBASE, Web of Science and Chinese electronic databases were analysed. The outcomes of interest were the number of PLHIV and AHD patients and their associated transmission routes. We assessed the risk of AHD among the different transmission routes using the multi-armed network meta-analysis based on the Bayesian method. The associations between AHD and regional policies for sex work and compulsory drug treatment were estimated using ecological linear regression. Findings: One hundred and one articles were included, covering 129,780 PLHIV with 478,830 patients who developed AHD. The network analysis revealed that among PLHIV, heterosexual contact was associated with the highest risk of AHD, followed by injection drug use (odds ratio [OR]=0•56, 95% credible interval [CrI] 0•47–0•68), and men who have sex with men (OR=0•54, 95% CrI 0•46–0•63). Regions that criminalized sex work and compulsory drug treatment had higher risks for AHD than those that did not. Interpretation: Our findings suggest HC is at a higher risk of AHD compared to IDU and MSM. This justifies the need to expand prevention campaigns and maintain efforts to increase HIV testing in the heterosexual population.
AB - Background: A substantial proportion of people living with HIV (PLHIV) present for care with advanced HIV disease (AHD), which may result in difficulty reaching the “90–90–90” target to end AIDS in 2030. We assessed the risk of AHD for different transmission routes to summarize the evidence for priority prevention strategies for key populations. Methods: Observational studies published before September 10th, 2019 in the PubMed, EMBASE, Web of Science and Chinese electronic databases were analysed. The outcomes of interest were the number of PLHIV and AHD patients and their associated transmission routes. We assessed the risk of AHD among the different transmission routes using the multi-armed network meta-analysis based on the Bayesian method. The associations between AHD and regional policies for sex work and compulsory drug treatment were estimated using ecological linear regression. Findings: One hundred and one articles were included, covering 129,780 PLHIV with 478,830 patients who developed AHD. The network analysis revealed that among PLHIV, heterosexual contact was associated with the highest risk of AHD, followed by injection drug use (odds ratio [OR]=0•56, 95% credible interval [CrI] 0•47–0•68), and men who have sex with men (OR=0•54, 95% CrI 0•46–0•63). Regions that criminalized sex work and compulsory drug treatment had higher risks for AHD than those that did not. Interpretation: Our findings suggest HC is at a higher risk of AHD compared to IDU and MSM. This justifies the need to expand prevention campaigns and maintain efforts to increase HIV testing in the heterosexual population.
UR - http://www.scopus.com/inward/record.url?scp=85074518258&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074518258&partnerID=8YFLogxK
U2 - 10.1016/j.eclinm.2019.10.003
DO - 10.1016/j.eclinm.2019.10.003
M3 - Article
C2 - 31832626
AN - SCOPUS:85074518258
VL - 16
SP - 121
EP - 128
JO - EClinicalMedicine
JF - EClinicalMedicine
SN - 2589-5370
ER -